On March 16, 2017, the Trump administration released its proposed budget outline for the 2018 federal fiscal year. The proposed plan would double the fees that pharmaceutical companies pay to have their products reviewed by the U.S. Food and Drug Administration (FDA), and says that it includes measures to speed up the approval process for new drugs … [Read more...]